000423 Dong-E-E-Jiao
- 70.22
- -0.13-0.18%
Dong-E-E-Jiao News
Dong-E-E-JiaoLtd's (SZSE:000423) Investors Will Be Pleased With Their Strong 122% Return Over the Last Three Years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money. For example, the Don
China Resources Pharmaceutical (03320.HK): Donga Ejiao's net profit of 353 million yuan in the first quarter increased 53.43% year-on-year
Gelonghui, April 26 | China Resources Pharmaceutical (03320.HK) announced that Donga Ejiao (000423.SZ)'s revenue for the first quarter of 2024 was 1,453 billion yuan, up 35.95% year on year; net profit attributable to shareholders of listed companies (Donga Ejiao) was 353 million yuan, up 53.43% year on year; net profit attributable to shareholders of listed companies (Donga Ejiao) after deducting non-recurring profit and loss was 329 million yuan, up 54.79% year on year; basic earnings per share were 0.5488 yuan.
Gelonghui announcement selection | Bull Group: 2023 net profit of 3.87 billion yuan, up 21.37% year on year; CNOOC: net profit of 39.719 billion yuan in the first quarter, up 23.7% year on year
[Performance Data] Kangchen Pharmaceutical (603590.SH): Net profit attributable to parent increased by 48.24% to 150 million yuan in 2023. Kangchen Pharmaceutical (603590.SH) will release the 2023 annual report. In 2023, the company achieved operating income of 920 million yuan, an increase of 6.15% over the same period of the previous year; net profit attributable to owners of the parent company was 150 million yuan, an increase of 48.24% over the same period last year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss was 127 million yuan, an increase of 42.51 million yuan over the same period of the previous year %; basic earnings per share 0.
Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Most readers would already be aware that Dong-E-E-JiaoLtd's (SZSE:000423) stock increased significantly by 36% over the past three months. But the company's key financial indicators appear to be dif
Dong-E-E-Jiao Forecasts Up to 55% Jump in Q1 Profit
Dong-E-E-Jiao (SHE:000423) expects its attributable profit to have jumped by about 45% to 55% to between 334 million yuan and 357 million yuan in the first quarter of 2024, according to a Friday filin
China Resources Pharmaceutical (03320.HK): Donga Ejiao's net profit for the first quarter is expected to be about 334 million to 357 million yuan
Gelonghui, April 12, 丨 China Resources Pharmaceutical (03320.HK) issued an announcement. On April 11, 2024, Donga Ejiao (000423.SZ) announced its results forecast for the three months ending March 31, 2024. According to this, the net profit attributable to shareholders of Donga Ejiao for the three months ending March 31, 2024 is estimated to be approximately RMB 334 million to RMB 357 million (approximately RMB 2303 million for the same period last year). Net profit after deducting non-recurring profit and loss is estimated to be approximately RMB 309 million to RMB 332 million ( Approximately RMB 2 for the same period last year.
Donga Ejiao (000423.SZ): Net profit expected to increase 45%-55% in the first quarter
Gelonghui, April 11 | Donga Ejiao (000423.SZ) announced its results forecast for the first quarter of 2024. Net profit attributable to shareholders of listed companies during the reporting period was 334 million yuan to 357 million yuan, an increase of 45%-55% over the same period last year; net profit after deducting non-recurring profit and loss was 309 million yuan to 332 million yuan, an increase of 46%-56% over the same period last year; basic earnings per share were 0.52 yuan/share — 0.55 yuan/share. In 2024, the company will closely focus on the development theme of “growth and quality” and deepen the implementation of “value reshaping and business focus”
Donga Ejiao (000423.SZ): As of March 29, 2024, the total number of shareholders of the company was 4,3666
Gelonghui, April 9 | Donga Ejiao (000423.SZ) said on the investor interactive platform that the latest data shows that as of March 29, 2024, the total number of shareholders of the company is 43,666.
Zhongtai Securities: Q1 results are about to be implemented, gradually focus on the pharmaceutical sector and individual stocks with improved Q2 performance
Zhongtai Securities said that at present, the overall market is still at a relative bottom. After experiencing a long-term correction, the pharmaceutical sector is also at multiple bottoms in terms of fundamentals, policies, and capital, and is firmly optimistic about the pharmaceutical sector market throughout the year.
Dong-E-E-JiaoLtd's (SZSE:000423) Earnings May Just Be The Starting Point
The subdued stock price reaction suggests that Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) strong earnings didn't offer any surprises. Investors are probably missing some underlying factors which are enco
2024 Financial Report | After the dividend ratio is close to 100%, Donga Ejiao still has 8 billion
Extravagant dividends
Private Companies Own 32% of Dong-E-E-Jiao Co.,Ltd. (SZSE:000423) Shares but Individual Investors Control 41% of the Company
Key Insights Dong-E-E-JiaoLtd's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by the to
Dong-E-E-Jiao's Profit Jumps 47.6% in 2023
Dong-E-E-Jiao (SHE:000423) recorded a net profit attributable to shareholders of 1.15 billion yuan in 2023, jumping 47.6% from the year-ago profit of almost 780 million yuan, according to the company'
China Resources Pharmaceutical (03320.HK): Donga Ejiao's net profit in 2023 increased by 47.55% to 1.151 billion yuan
Gelonghui, March 22丨China Resources Pharmaceutical (03320.HK) announced that in 2023, Donga Ejiao (000423.SZ) achieved operating income of RMB 4.715 billion, up 16.66% year on year; net profit attributable to shareholders of listed companies was RMB 1.151 billion, up 47.55% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 1,083 million, up 54.70% year on year; basic earnings per share were 1.79 yuan.
Donga Ejiao (000423.SZ): 2023 net profit pre-increased by 41%-49%
Gelonghui, January 26 | Donga Ejiao (000423.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 110,000-116 million yuan, an increase of 41%-49% over the same period of the previous year; net profit after deducting non-recurring profit and loss was 103,000-110,000 yuan, an increase of 47%-57% over the same period last year; basic earnings per share were 1.71 yuan/share - 1.80 yuan/share. In 2023, the company closely focused on the development theme of “growth and efficiency” and continued to deeply implement “value reshaping and business reshaping”
Donga Ejiao (000423.SZ): The repurchase was completed with a cumulative cost of 758.724 million yuan to buy back 1,512,400 shares
Gelonghui, January 24 | Donga Ejiao (000423.SZ) announced that as of the announcement disclosure date, the company had completed the repurchase and had actually repurchased 1,512,400 shares of the company's shares, accounting for 0.2349% of the company's total share capital. The maximum repurchase price was 52.41 yuan/share, the minimum repurchase price was 48.01 yuan/share, and the total amount of capital used was 758.724 million yuan (excluding transaction fees).
Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) Stock Going Strong But Fundamentals Look Weak: What Implications Could This Have On The Stock?
Dong-E-E-JiaoLtd's (SZSE:000423) stock is up by a considerable 12% over the past three months. However, we decided to pay close attention to its weak financials as we are doubtful that the current m
Donga Ejiao (000423.SZ): Initial repurchase of 200,000 shares involving 9.9937 million yuan
Gelonghui, January 10 | Donga Ejiao (000423.SZ) announced that on January 10, 2024, the company repurchased the company's shares through centralized bidding transactions for the first time through a special stock repurchase securities account. The number of shares repurchased was 200,000 shares, accounting for 0.0311% of the company's current total share capital. The highest transaction price was 50.36 yuan/share, the minimum transaction price was 49.64 yuan/share, and the total transaction amount was RMB 9.9937 million (excluding transaction fees).
Damo: Target price of HK$7.8 for China Resources Pharmaceuticals “gain” rating
Damo released a research report stating that it is believed that the stock price of China Resources Pharmaceuticals (03320) will rise within 30 days, the rating will “increase”, and the target price is HK$7.8. Donga Ejiao (000423.SZ) and Jiangzhong Pharmaceutical (600750.SH), of the five A-share subsidiaries directly under China Resources Pharmaceutical, announced new management incentive plans, all in the form of restricted shares, and both cover profit performance from 2022 to 2026. The bank believes that the management incentive plans of the two companies reflect current expectations that there is room for improvement.
Gelonghui Announcements Selected | Delong Laser: Plans to invest 450 million yuan to build a headquarters R&D center and laser industry base; Spatio-temporal Technology: Does not carry out “spatial computing” and “virtual reality” business and technology
[Hot Focus] Jinchen Co., Ltd. (603396.SH): Up to now, the company's HJT battery equipment has not generated revenue Jinchen Shares (603396.SH) announced abnormal stock trading fluctuations. Currently, the company's main products are complete equipment for automated production lines of solar photovoltaic modules and solar photovoltaic cell manufacturing equipment. There are media reports that the company is involved in the HJT battery concept. Up to now, the company's HJT battery equipment has not generated revenue. According to the company's own inspection, all of the company's daily business activities are normal, and there have been no major adjustments in the market environment or industry policies. There are no production and operation aspects of the company that should be disclosed
Analysis
Price Target
No Data
